Featured20 November 2026Neuroendocrine tumours: SSTR imaging and PRRTDosimetry in radionuclide therapy
Does the tumour absorbed dose predict survival with Lu-177 DOTATATE?
A post hoc analysis of the Swedish phase 2 ILUMINET trial (Warfvinge et al., J Nucl Med, October 2026) reported that, in 81 patients with grade 1-2 neuroendocrine tumours treated with [177Lu]Lu-DOTATATE, the mean absorbed dose to the whole tumour burden was independently associated with progression-free and overall survival. This article summarises the study, how the dose was measured, and earlier studies that asked the same question.
Why tumour dose?
Approval of [177Lu]Lu-DOTATATE rests on the NETTER-1 trial, in which all patients received 4 × 7.4 GBq 2. Studies that individualised the administered activity by the dose to organs at risk (mainly the kidneys) found the approach feasible but, in the authors' assessment, did not show a clinical benefit over the standard regimen 1,3. Attention has recently shifted to the dose received by the tumour; studies on this were small, mostly measured only selected lesions and lacked multivariable survival analysis 1.
What did the study do?
- Patients and treatment (ILUMINET) [1, 3]: Phase 2, non-randomised, two Swedish centres, 2011-2019; SSTR-positive NETs with Ki-67 ≤20%. Cycles of 7.4 GBq were given 8-12 weeks apart; kidney dosimetry was done for every cycle and treatment stopped when the cumulative renal biologically effective dose reached 27 Gy (up to 40 Gy in patients under 70 with preserved renal and haematological function and no progression). Of 103 enrolled patients, 81 were analysed (80 for cumulative dose).
- How was tumour dose measured? [1]: Quantitative SPECT at every cycle (with attenuation, scatter and collimator-response compensation); tumours were segmented automatically on SPECT and confirmed by an oncologist on CT or MRI at the first cycle; partial-volume correction per tumour. Dose was calculated assuming an effective half-life of 103 h for grade 1 and 81 h for grade 2 NETs. The patient dose is the mass-weighted mean over all tumours (energy deposited per total tumour mass); the cumulative dose is the sum over cycles. In total, 2,295 tumour volumes were measured.
- Analysis [1]: Patients were split at the median dose and also into quartiles; Kaplan-Meier and a multivariable Cox model (tumour grade, ECOG performance status, age, prior treatment other than SSA).
Findings
- Dose distribution: Median tumour dose was 19 Gy at cycle 1 and 74 Gy cumulatively; quartile limits of the cumulative dose were 46 and 118 Gy. Pancreatic tumours consistently received higher doses than small-intestinal ones 1.
- Above and below the median (cumulative dose): In the ≥74 Gy group, median progression-free survival (PFS) was 47.1 months and overall survival (OS) 88.4 months; in the <74 Gy group 23.1 and 45.1 months. In the multivariable model the hazard ratio (HR) was 0.37 (95% CI 0.21-0.66) for PFS and 0.48 (0.25-0.93) for OS. With the cycle 1 dose (19 Gy cut-off) the HRs were 0.34 and 0.41 1.
- Top quartile (>118 Gy): Median PFS 50.9 months, median OS not reached; 26.4 and 45.1 months in the lower three quartiles. Multivariable HR 0.27 for PFS and 0.28 for OS. The number of grade ≥3 adverse events did not differ between quartiles (4-5 events per quartile). Median follow-up 47 months 1.
- How were these doses reached? Of the 20 patients above 118 Gy, 14 needed more than 4 cycles to get there; none exceeded a cumulative renal biologically effective dose of 28 Gy 1.
Context: other studies asking the same question
- Hebert et al., J Nucl Med 2024 [4]: Montpellier; 35 dosimetry studies, up to 5 lesions per site selected and measured. Patients whose selected lesions had a mean total dose above 91.36 Gy had longer PFS (HR 0.39) but no significant OS difference (HR 0.34, p = 0.06); those whose lowest-dose lesion exceeded 52.52 Gy had better PFS and OS.
- Maccauro et al., LUTADOSE, Eur J Nucl Med Mol Imaging [5]: 42 patients on the standard 4 × 7.4 GBq; with the mass-weighted tumour dose after cycle 1 below and above a 10.6 Gy cut-off, median PFS was 21 months versus not reached (HR 8.6).
- The thresholds are not directly comparable: The studies measured all tumours or selected lesions, the mean or the lowest dose, a single cycle or the cumulative dose. Warfvinge et al. write that the next step is a standard definition of what is measured in tumour dosimetry 1.
Practical points
- An association, not a proven target: The analysis is post hoc; 118 Gy is a quartile limit of this cohort and the authors present it as a candidate target for future studies. That treatment planned by tumour dose prolongs survival has not yet been shown in a randomised trial; the authors also call for prospective trials 1.
- The groups were not alike in every respect: Pancreatic tumours and ECOG 0 were somewhat more frequent in the high-dose groups, small-intestinal tumours in the low-dose groups. Replacing grade with tumour origin in the model gave similar results 1.
- The measurement depends on the method: Dose was calculated with an effective half-life fixed by grade rather than measured for each tumour, and tumour definition relied on SPECT uptake (tumours with low uptake may have been missed). Before using a number in another centre, the same method should be confirmed 1.
- The regimen was not the standard one: Most patients were treated with a kidney-dosimetry-guided regimen that allowed more than 4 cycles; the results cannot be transferred directly to the standard 4-cycle regimen 1,3.
Test yourself
In the ILUMINET analysis by Warfvinge et al. (J Nucl Med 2026), how was each patient's tumour dose summarised?
In the same study, which is true for patients in the top quartile of cumulative tumour dose (>118 Gy)?
In the ILUMINET trial, what determined the number of [177Lu]Lu-DOTATATE cycles?
References
- Warfvinge CF, Kapidzic SC, Gustafsson J, Jessen L, Svensson J, Sundlöv A, Sjögreen Gleisner K. Patient survival and its relation to tumor absorbed dose in [177Lu]Lu-DOTATATE therapy of neuroendocrine tumors. J Nucl Med. 2026;67(10):1586-1594. doi:10.2967/jnumed.125.271439 PMID 42562609
- Strosberg JR, Caplin ME, Kunz PL, et al. 177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22(12):1752-1763. doi:10.1016/S1470-2045(21)00572-6 PMID 34793718
- Sundlöv A, Gleisner KS, Tennvall J, et al. Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients. Eur J Nucl Med Mol Imaging. 2022;49(11):3830-3840. doi:10.1007/s00259-022-05786-w PMID 35451612
- Hebert K, Santoro L, Monnier M, et al. Absorbed dose-response relationship in patients with gastroenteropancreatic neuroendocrine tumors treated with [177Lu]Lu-DOTATATE: one step closer to personalized medicine. J Nucl Med. 2024;65(6):923-930. doi:10.2967/jnumed.123.267023 PMID 38637144
- Maccauro M, Cuomo M, Bauckneht M, et al. The LUTADOSE trial: tumour dosimetry after the first administration predicts progression free survival in gastro-entero-pancreatic neuroendocrine tumours (GEP NETs) patients treated with [177Lu]Lu-DOTATATE. Eur J Nucl Med Mol Imaging. 2024;52(1):291-304. doi:10.1007/s00259-024-06863-y PMID 39235614
Citing this piece
If you use this piece in a presentation, paper or thesis, add this line to your reference list (Vancouver style). "Copy" puts it on your clipboard; to cite the studies it reviews, use the numbered references above.
Nuclear Medicine Explained. Does the tumour absorbed dose predict survival with Lu-177 DOTATATE? [Internet]. Last updated 20 November 2026. Available from: https://nuclearmedicineexplained.com/en/updates/lu-177-dotatate-tumour-dose-survival
Published after physician editor approval · last updated 20 November 2026
Revision history
- 20 November 2026: First draft. The main study's full text (open access, CC BY) and tables were read; thresholds of the context studies were verified in the primary sources; details from PubMed.
- 20 November 2026: Article and three "Test yourself" questions published after physician editor approval.
Prepared by Claude from primary sources and published after approval by the physician editor. It summarises what the evidence says; it is not a treatment recommendation.